• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Allied Minds launches Novare Pharmaceuticals

Allied Minds launches Novare Pharmaceuticals

October 8, 2014
CenterWatch Staff

Allied Minds, a Boston, Mass.-based science and technology development and commercialization company, has launched Novare Pharmaceuticals, a biotechnology company focused on developing therapeutic products that help the body replenish and rebuild itself using its own tissue through the modulation of Receptor for Hyaluronan Mediated Motility (RHAMM). Modulation of RHAMM also is of benefit in inflammatory diseases such as bronchopulmonary dysplasia (BPD).

Novare is an expansion of the Allied Minds subsidiary previously called ProGDerm, which is developing a dermal filler for aesthetic applications that works via the modulation of the RHAMM. This research is being led by Dr. Eva Turley, an oncology scientist at the London Health Sciences Center (LHSC) in London, Ontario, in collaboration with MJ Bissell, a cell biologist at Lawrence Berkeley National Laboratories in Berkeley, Calif. Turley and colleagues now have uncovered the potential for additional applications of RHAMM modulation that may help solve medical challenges including arthritis, fibrotic diseases such as BPD in premature infants and idiopathic pulmonary fibrosis and the reduction and possible elimination of keloid scars.

This breakthrough in tissue engineering also may provide an opportunity to regenerate and reconstruct women's breasts after a mastectomy through the localized stimulation of the body's own adipocyte (fat) stem cells. Novare has licensed from LHSC additional RHAMM compounds discovered by Turley, who also is Novare's chief scientist, and Dr. Leonard Luyt, a peptide chemist at LHSC, allowing the company to more than double its library of RHAMM-binding peptides—and increase potential applications.

RHAMM is a protein that is normally localized inside the cell but is released by certain stimuli. It plays a role in the regulation of spontaneous cell movement and stem cell differentiation. Turley and colleagues found that modulating RHAMM provides the safest and most efficacious means to selectively promote subcutaneous fat generation (adipogenesis), moderate destructive inflammation and reduce scarring (fibrosis) by stimulating normal cell differentiation and controlling the body's own natural regenerative processes.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing